Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours
Carregando...
Arquivos
Fonte externa
Fonte externa
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Oxford University Press
Tipo
Artigo
Direito de acesso
Acesso restrito
Arquivos
Fonte externa
Fonte externa
Resumo
Background: The clinical relevance of transforming growth factor-beta (TGF-beta)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-beta and transforming growth factor-beta type II receptor (TGF-beta RII) expression levels in tumour cells and their association with the established biomarkers in BC.Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-beta 1 and TGF-beta RII transcript and protein expression levels were assessed.Results: TGF-beta 1 and TGF-beta RII down-expression was significantly associated with BC. Negative TGF-beta 1 and TGF-beta RII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-beta 1-positive tumours were associated with increased disease-free survival (DFS) [hazard ratio (HR) = 0.489, P = 0.003]. TGF-beta RII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor2 (HER2)-negative patients. Absence of TGF-beta 1 and TGF-beta RII proteins in breast tumour cells was significantly associated with metastasis development.Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-beta RII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-beta RII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC.
Descrição
Palavras-chave
breast cancer, HER2, prognostic markers, TGF-beta 1, TGF-beta RII
Idioma
Inglês
Citação
Annals of Oncology. Oxford: Oxford Univ Press, v. 21, n. 4, p. 734-740, 2010.
